News | August 07, 2024
Sucralose safe to use in small doses; reveals MDRF study
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Subscribe To Our Newsletter & Stay Updated
